We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+15.27%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$17.3B
AUM Growth
+$1.38B
Cap. Flow
-$440M
Cap. Flow %
-2.54%
Top 10 Hldgs %
32.07%
Holding
728
New
61
Increased
216
Reduced
343
Closed
55

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$85M
2
ABT icon
Abbott
ABT
+$53.8M
3
EXC icon
Exelon
EXC
+$46.6M
4
BSX icon
Boston Scientific
BSX
+$42.6M
5
ABBV icon
AbbVie
ABBV
+$32.4M

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$80.5M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$54.5M
3
CRWD icon
CrowdStrike
CRWD
+$45.7M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$40.6M
5
MRK icon
Merck
MRK
+$39.3M

Sector Composition

Rank Sector Weight
1 Technology 36.26%
2 Healthcare 22.78%
3 Financials 10.33%
4 Consumer Discretionary 7.75%
5 Industrials 7.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
USB icon
126
US Bancorp
USB
$99.6B
$26.6M 0.15%
587,001
+232,616
+66% +$9.78M
BRKR icon
127
Bruker
BRKR
$9.2B
$26.5M 0.15%
642,990
+263,963
+70% +$10.2M
RVMD icon
128
Revolution Medicines
RVMD
$40.2B
$26.5M 0.15%
719,513
+64,379
+10% +$2.47M
ELV icon
129
Elevance Health
ELV
$81.9B
$26.2M 0.15%
67,469
+13,638
+25% +$5.49M
HOLX
130
DELISTED
Hologic
HOLX
$26M 0.15%
399,277
-30,864
-7% -$1.85M
EXEL icon
131
Exelixis
EXEL
$13.9B
$25.9M 0.15%
587,737
+232,597
+65% +$9.3M
KEYS icon
132
Keysight
KEYS
$54.5B
$25.9M 0.15%
157,903
-45,380
-22% -$6.92M
BRO icon
133
Brown & Brown
BRO
$22.9B
$25.5M 0.15%
230,393
-42,650
-16% -$4.79M
MCD icon
134
McDonald's
MCD
$188B
$25.2M 0.15%
86,315
-7,376
-8% -$2.27M
TGT icon
135
Target
TGT
$62.1B
$25.2M 0.15%
254,965
+213,097
+509% +$20.5M
ARGX icon
136
argenx
ARGX
$57.4B
$25.1M 0.14%
45,567
+4,287
+10% +$2.49M
LULU icon
137
lululemon athletica
LULU
$13B
$25M 0.14%
105,323
+34,880
+50% +$9.61M
CI icon
138
Cigna
CI
$76.6B
$24.8M 0.14%
74,949
-98,682
-57% -$31.8M
OC icon
139
Owens Corning
OC
$11.5B
$24.5M 0.14%
178,405
-42,307
-19% -$5.84M
VLTO icon
140
Veralto
VLTO
$22.6B
$24.5M 0.14%
242,684
-16,003
-6% -$1.54M
LRN icon
141
Stride
LRN
$3.69B
$24.1M 0.14%
166,146
-22,997
-12% -$3.33M
PODD icon
142
Insulet
PODD
$11.3B
$24.1M 0.14%
76,762
+23,570
+44% +$6.8M
TOST icon
143
Toast
TOST
$16.8B
$24.1M 0.14%
543,155
+431,172
+385% +$16.9M
UTHR icon
144
United Therapeutics
UTHR
$26.3B
$23.9M 0.14%
83,211
+3,998
+5% +$1.19M
EGO icon
145
Eldorado Gold
EGO
$8.31B
$23.8M 0.14%
1,172,500
-449,426
-28% -$8.75M
MDB icon
146
MongoDB
MDB
$24B
$23.3M 0.13%
111,056
+500
+0.5% +$92.4K
CM icon
147
Canadian Imperial Bank of Commerce
CM
$107B
$23.1M 0.13%
326,589
-22,616
-6% -$1.46M
NUVL
148
DELISTED
Nuvalent
NUVL
$23M 0.13%
301,259
-52,870
-15% -$3.87M
PAYC icon
149
Paycom
PAYC
$6.78B
$22.9M 0.13%
99,023
+28,319
+40% +$6.71M
TPR icon
150
Tapestry
TPR
$28.8B
$22.9M 0.13%
+260,834
New +$19.8M

Similar funds

Candriam SCA's Q2 2025 Portfolio in Review

As of Q2 2025, Candriam SCA held 728 positions worth $17.3B, up 8.6% from $16B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Candriam SCA's Q2 2025 filing shows 61 new, 216 increased, 343 reduced and 55 closed positions. Its largest new stake was Tapestry: 260,834 shares worth $22.9M. The largest sale was Tesla, an estimated $80.5M.

By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q2 2025 buy was Tapestry: 260,834 shares worth $22.9M.
  • Candriam SCA added most to Broadcom in Q2 2025, an estimated $85M increase.
  • Candriam SCA's biggest Q2 2025 reduction was Tesla, cutting an estimated $80.5M.
  • Candriam SCA fully exited Banco Macro in Q2 2025, selling an estimated $17.6M.
  • Candriam SCA's ten largest holdings make up 32% of its $17.3B portfolio in Q2 2025.
  • Candriam SCA opened 61 new positions and closed 55 in Q2 2025.
  • Candriam SCA's portfolio value rose 8.6% quarter-over-quarter to $17.3B.

Based on Candriam SCA's 13F filing for Q2 2025, filed 8 Aug 2025.